Why Avalo Therapeutics, Inc.’s (AVTX) Stock Is Up 6.37%
As of Monday, July 27, Avalo Therapeutics, Inc.’s AVTX share price has surged by 6.37%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Commentary & Analysis
Why Avalo Therapeutics, Inc.’s (AVTX) Stock Is Down 5.89%
As of Monday, July 20, Avalo Therapeutics, Inc.’s AVTX share price has dipped by 5.89%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Avalo Therapeutics, Inc.’s (AVTX) Stock Is Up 6.52%
As of Friday, July 17, Avalo Therapeutics, Inc.’s AVTX share price has surged by 6.52%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Avalo Therapeutics, Inc.’s (AVTX) Stock Is Down 6.02%
As of Friday, July 10, Avalo Therapeutics, Inc.’s AVTX share price has dipped by 6.02%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Avalo Therapeutics, Inc.’s (AVTX) Stock Is Up 6.63%
As of Monday, July 06, Avalo Therapeutics, Inc.’s AVTX share price has surged by 6.63%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | AVTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $965.5 | $252.6 | 45% |
|
| Shares Out (Mil) | 20.1 | 52.3 | 31% |
|
| Institutional Ownership | 97.6% | 92.1% | 75% |
|
| Float (Mil) | 40.7 | 40.2 | 43% |
|
| Beta | 0.79 | 0.95 | 46% |
|
| Avg Daily Volume (000s) | 842 | 455 | 67% |
|
| Price Change (52-week) |
174.0% | 52.9% | 97% |
|
| Growth | AVTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (4.3%) | (9.9%) | 34% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.6%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 11 | 11 | |
| Current EPS | ($0.617) | ($2.556) | ($2.765) | |
| Month Ago EPS | ($0.618) | ($2.623) | ($2.800) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.937) | ($3.389) | ($3.460) | |
| Year/Year Chg | (36.8%) | (56.2%) | (54.8%) | |
| Financials | AVTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($85) | ($43) | 12% |
|
| EPS (TTM) | ($5.362) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($60) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($100) | $5 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $748 | $180 | 38% |
|
| Valuation | AVTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.59 | 2.56 | 84% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AVTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (71.1%) | (49.8%) | 8% |
|
| ROE | (88.8%) | (55.5%) | 10% |
|
| Liabilities to Assets | 31.6% | 30.3% | 23% |
|
| F-Score | 2 | 3 | 7% |
|
Avalo Therapeutics, Inc. did not pass any screens on 7/31/2026.
